Arvinas reports preclinical data showing ARV-393 + glofitamab combo yields up to 91% TGI in lymphoma model

ARVINAS, INC.

ARV-393 (3 mg/kg) + glofitamab achieved 81% TGI (concomitant) and 91% TGI (sequential) vs 38% and 36% single-agent.
At 6 mg/kg ARV-393 combo, tumor regressions in 10/10 mice (concomitant) and 7/8 (sequential) vs 5/11 and 0/11 alone.
RNA-seq showed ARV-393 upregulated CD20, interferon signaling, antigen presentation; downregulated proliferation genes.
Phase 1 trial of ARV-393 in relapsed/refractory non-Hodgkin lymphoma ongoing; clinical data due at medical congress in 2026.
Company plans to add glofitamab combination cohort in DLBCL to ongoing Phase 1 trial in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.